Hepatocellular Carcinoma
Conditions
Brief summary
The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.
Interventions
DRUGQL1706
7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
DRUGBevacizumab
15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
DRUGCapecitabine
1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
DRUGSintilimab
200 mg administered as IV infusion on Day 1 of each 21-day cycle
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects participate voluntarily and sign informed consent. 2. Age ≥ 18 and ≤ 80 years old, male or female. 3. Histological or cytological or clinical diagnosis of HCC 4. Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment. 5. No prior systemic therapy for HCC. 6. Child-Pugh ≤7 , no history of hepatic encephalopathy.
Exclusion criteria
1. Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc. 2. History of malignancy other than HCC within 5 years prior to the start of study treatment. 3. History of liver transplantation, or planned to receive liver transplantation. 4. Moderate or severe ascites with clinical symptoms that require drainage, uncontrolled or moderate or severe pleural and pericardical effusion. 5. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 6. Involvement of both the main portal vein and the left and right branches by portal vein tumor thrombus, or of both the main trunk and the superior mesenteric vein concurrently, or of inferior vena cava.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) (Phase II) | Up to approximately 4 years | ORR was assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). |
| Incidence of Adverse Events (AEs) (Phase II) | Up to approximately 4 years | An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. |
| Overall Survival (OS) (Phase III) | Up to approximately 4 years | OS was defined as the time from randomization to death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Up to approximately 4 years | PFS was assessed by investigators per RECIST 1.1 |
| Objective Response Rate (ORR) | Up to approximately 4 years | ORR was assessed by investigators per RECIST 1.1 |
| Time to progression (TTP) | Up to approximately 4 years | TTP was assessed by investigators per RECIST 1.1 |
| Disease Control Rate (DCR) | Up to approximately 4 years | DCR was assessed by investigators per RECIST 1.1 |
| Duration of Response (DOR) | Up to approximately 4 years | DOR was assessed by investigators per RECIST 1.1 |
Countries
China
Contacts
Primary ContactJian Gao
Outcome results
None listed